Dr. Ioannis Tarnanas, Ph.D.

Dr. Ioannis Tarnanas, Ph.D. has had a varied and distinguished career. Dr. Ioannis began their work experience in 2001 as a Senior Clinical Project Manager for the Western Macedonia Research Center in Greece and the Virtual Reality Medical Center in the United States. In 2008, they took on the role of Senior Clinical Manager at the Virtual Reality Medical Institute in San Diego, California. In 2010, they moved to Alzheimer Association Hellas as a Senior Clinical Specialist, where they applied their experience in Virtual Reality, EEG resting state signal analysis, and event related potentials for early screening of Alzheimer's. In 2013, they joined the ARTORG Center for Biomedical Engineering Research at the University of Bern. In 2014, they founded XtremeVRI AG, which developed Alterniity AR, an Augmented Reality based early diagnostic technology for older people at risk of dementia. In 2016, they were a Founder at Altoida, Inc. and a Senior Director Clinical Research at Healthbrain Corp. Dr. Ioannis also became an Atlantic Fellow for Equity in Brain Health at the Global Brain Health Institute. In 2019, they became an Expert Evaluator at EIT Health.

Dr. Ioannis Tarnanas, Ph.D. has a diverse educational background. Dr. Ioannis obtained their Doctor of Philosophy (Ph.D.) in Neurology from the Aristotle University of Thessaloniki (AUTH) in 2015, after completing their Master of Science in Human Centered Computer Systems from the University of Sussex in 1999. Their undergraduate studies were completed at AUTH in 1998, where they obtained a degree in Cognitive Psychology. More recently, they were an Atlantic Fellow with the Global Brain Health Institute at Trinity College Dublin from 2017 to 2018, and an Atlantic Fellow with the Global Brain Health Institute at the University of California, San Francisco from 2019 to 2020, studying Brain Health policy and economics. Dr. Ioannis has also obtained certifications in ESET cybersecurity awareness training in 2021 and DECIDE computer-aided extraction of diagnostic markers for Alzheimer’s disease as a service to the Alzheimer’s clinical community in 2013.